SPRY ARS Pharmaceuticals Inc

$SPRY $AQST Poor SPRY longs lost 75% of their money YTD on their one drug company. They have every right to be Bitter!!!! AQST has 4 on the market with a superior drug to SPRY. Only an imbecile would buy SPRY

$SPRY Stone52’s post back at the beginning of the year. All his posts are desperation trying to convince himself he made a good decision buying SPRY at 10. Here’s his post………..,………..$SPRY could be bought out by ALK-Abello, their partner ex-US, who has a 45 Billion market cap. On ALK-Abello conference call Friday, they said their 2026 focus is Neffy - but that it has lower margins (due to royalties), so the company guided for lower margins overall. How to rectify? Buy ARS.

$SPRY - I'm betting on Donn Casale to execute his plan based on his past performance in other leadership positions. IMO, a steal here. Not looking for the moon, but $8-10/sh very achievable within a year. Just bought 10,000 sh.

$SPRY with such poor sales and poor management, they’re going to have to raise capital soon.

$SPRY 42% organic patient demand growth year over year. 49% unique prescriber expansion year-over-year. Very impressive considering they cut out all their TV ads. Revenue will follow as warehouses have to order new stock. The demand is there and expanding. Gl

$SPRY Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.36 up 30.77% YoY • Reported revenue of $37.71M up 16.03% YoY • ARS Pharmaceuticals' second-half 2026 aggregate SG&A and R&D guidance is $114M to $126M, including stock-based compensation; ARS continues to expect cash flow breakeven by the end of 2027.

$SPRY Interesting parallels between $DVAX (acquired by $SNY) and $SPRY 👀 In February 2025, Dynavax executives received significant stock option awards. Just 10 months later, Sanofi announced its $2.2 BILLION acquisition. Now look at $SPRY. CEO Donn Casale, CCO Meg Smith, and new Chief Legal Officer John Slebir-who previously worked alongside Donn and Meg at Dynavax-are reunited as executive equity awards draw attention. Experienced leadership. Significant stock incentives. Global licensing opportunities. Expanding neffy commercialization. Could this team be positioning $SPRY for something much bigger? History doesn’t guarantee a repeat, but the connections are intriguing. NFA.

$SPRY how is your pumping working you? why not do more spamming? perhaps someone as supid as you and bean will invest in this POS. And don't forget to like your posts.

$SPRY made about 5k on the bounce from 2.50 as I guaranteed. Next step will be down to 1s.

$SPRY Only trade swing shares in this stock. Buying long shares here is not a good idea. It will hover over 2.50 and then go under, like to sub $1.

$SPRY vs. $AQST An overlooked neffy advantage. Even if Anaphylm receives FDA approval in March 2027, pediatric restrictions remain. neffy is FDA-approved for children as light as 33 lbs (15 kg). Anaphylm’s proposed minimum is 66 lbs (30 kg). That gives neffy a meaningful advantage for smaller children. Add neffy’s first-to-market position, growing prescriber base, and expanding insurance access. FDA approval doesn’t mean competitive parity. $SPRY has advantages $AQST cannot immediately replicate.

$SPRY Not the move I was expecting this morning. Nobody wants this turd. It's not a bad turd.

$SPRY Don’t let the earnings miss overshadow the positives. 📈 U.S. neffy sales reached $33.4M, up 27.5% QoQ, with growing market share. 🌎 Global expansion through ALK, Alfresa, Pediatrix & CSL Seqirus offers recurring royalties, licensing milestones and supply revenue. 💰 The $12.5M investment in exclusive worldwide IP rights could unlock new products, licensing opportunities and future royalty streams, as Donn Casale discussed today. 🔬 CSU (chronic spontaneous urticaria) offers significant upside beyond anaphylaxis, with Phase 2b interim data expected Q1 2027. 📉 Management is cutting SG&A as promised, targeting over 40% lower cash SG&A spending in H2 vs. H1 2026. Cash-flow breakeven remains targeted for YE 2027. Cash burn and the revenue miss remain concerns. But growing sales, global royalties, product expansion, CSU catalysts and improving financial discipline shouldn’t be overlooked. $SPRY is building a global pharmaceutical platform, not just a single-product U.S. business.

$SPRY love it all. Keeps allowing me to add. Let the vultures come. Incredible set up for the mid to long term holders here.

$SPRY All Time Low on this POS is 2.55....Actual All time Low at Closing 2.92.....Way Before this Neffy Garbage was Approved

$SPRY Regulatory Approval in at least 35 countries, you'd think the Neffy solution would be able to sell itself. What a sad PPS!

$SPRY this enthusiast (he thinks he very funny, which tells you a lot about intellectudl level of aqst crowd) has no idea what’s coming for $AQST. This management cant be trusted. Dilution, citizen petitition and/or another crl are in order. Your best bet is a black box warning and limited use for adults only

$SPRY No one cares about CVS... This company will run out of money anyway... Possible pump into CVS but they will do an offering...

$SPRY countdown is on. Less than 30 days until earnings and cvs decision…exciting times to come!

$SPRY made real good money here when fda denied it dirst round now loading again hee for a good pop